anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to a sodium alginate film and its preparation method. According to the invention, the sodium alginate film is obtained by freeze-drying molding of sodium alginate and polyvinyl alcohol which are used as structure carriers. The preparation method comprises the following steps: dissolving PVA in water of 75-85 DEG C, and filtering to obtain a PVA aqueous solution; adding sodium alginate into the PVA aqueous solution, stirring, and pouring the solution into a mold; freeze-drying the mold at the temperature of minus 35-10 DEG C to obtain a porous and flexible freeze-dried film in the mold; taking the freeze-dried film out, adding the freeze-fried film into an ethanol aqueous solution of CaCl2, immersing, washing and airing to obtain the sodium alginate film. The sodium alginate film provided by the invention is porous and ventilated, has good elasticity, good flexibility, high water absorption and the like, and has fine and tough pores. The sodium alginate film has effects of resisting oxidation, maintaining beauty and keeping young, has a certain effects of diminishing inflammation and promoting wound healing, and has good disinfection and sterilization effects. The preparation method provided by the invention is simple and highly-efficient.
The highest dose of tolcapone administered to humans was 800 mg tid, with and without levodopa/carbidopa co-administration. This was in a 1-week study in elderly, healthy volunteers. The peak plasma concentrations of tolcapone at this dose were on average 30 mcg/mL (compared to 3 mcg/mL and 6 mcg/mL with 100 mg and 200 mg tolcapone, respectively). Nausea, vomiting and dizziness were observed, particularly in combination with levodopa/carbidopa.

The threshold for the lethal plasma concentration for tolcapone based on animal data is >100 mcg/mL. Respiratory difficulties were observed in rats at high oral (gavage) and intravenous doses and in dogs with rapidly injected intravenous doses.
PROBLEM TO BE SOLVED: To obtain the subject medicine having excellent neurocladism action on central nervous cells, especially aged central nervous cells and useful as a therapeutic agent including an antidemential agent for neurodegenerative diseases by including a compound derived from a specific cellular mucosa. SOLUTION: This medicine comprises dictyosterol of the formula as an active ingredient. The compound of the formula can be obtained by culturing a cellular mucosa, extracting the compound of the formula which is intracellularly present with an organic solvent after finishing the culture, isolating the compound of the formula in the extract from the crude product by using a usually known purification method and washing the isolated compound with an organic solvent. The compound of the formula is preferably produced by culturing the cellular mucosa for 7-10 days by agar plate culturing method. The culturing temperature is suitably 20-25 deg.C. A form and a pathway which are pharmaceutically hitherto well-known are applied for administration of the medicine and the medicine is preferably administered at a daily dose of 0.001-100 mg divided into one to several portions.
The current research study will evaluate changes in body weight and composition, assess determinants of energy balance, and measure modulators of energy intake and expenditure, following 8 wk of calorie restriction (CR, -500 kcal/d) in combination with either overnight exposure to normobaric hypoxia (NH) or normoxia (NN). Participants will be instructed to follow their normal diet but with a 500 kcal/day deficit as advised by a Registered Dietitian. Participants will spend 8 hours/night in a tent, set-up around their bed, in their home, for 8 weeks. Participants sleeping in the hypoxic tent (Hypoxico Inc., New York, NY, commercially available tents: https://hypoxico.com/) will breath \~15% oxygen (achieved with nitrogen dilution, equivalent to \~8500 ft elevation), whereas those in the control tent (Hypoxico Inc.) will breath \~21% oxygen (achieved with nitrogen dilution, equivalent to sea level elevation). Trained research staff will set-up the hypoxic or control tent system in each participant's home on day 0 and will visit the participant's home on days 1, 2, and 3 to check and/or adjust the tent settings. After day 3, research staff will visit the participant's home weekly to check and/or adjust the tent settings. participants will be weighed each morning following an overnight fast and morning void. Participants will come to the laboratory on two separate days for baseline testing (days -1 and 0) and again on two separate days at the end of the study (days 55 and 56) for endpoint testing.
Background: Lymphedema is a common breast cancer side effect, with an average incidence of 30%. The gold standard conservative treatment for lymphedema is complex decongestive therapy (CDT), which includes manual lymphatic drainage, compression therapy, skin care, and exercise. Lymphovenular anastomosis (LVA) is a microsurgical technique that intends to redirect excess lymphatic fluid to the venous circulation; this procedure is usually performed when conservative treatment fails. Therefore, the objective of this study is to evaluate the effectiveness of LVA and CDT for the treatment of breast cancer-related lymphedema (BCRL). Methods and Results: The search was performed in CENTRAL, MEDLINE, Embase, PsycINFO, SCOPUS, and LILACS. Inclusion criteria were (1) population: women with BCRL; (2) intervention: treated with LVA and CDT; and (3) outcome: primary outcome was lymphedema reduction. Secondary outcome was quality of life. Risk of bias and quality of study reporting were also assessed. The search found 3872 articles, with 5 articles meeting the PICO (population, intervention, comparison, outcomes) criteria, 4 pre-post studies, and one observational cohort study. The total sample included 2763 patients. Follow-up was variable. The follow-up varies from 7.8 to 120 months, with an average of 35 months. Lymphedema reduction was obtained in the five studies. Conclusion: The present systematic review suggests that for patients with lymphedema secondary to breast cancer, the combination of both treatments is effective in reducing the size of the limb and improving quality of life. Low-quality evidence was found for both limb circumference reduction and quality of life. Additional research effort is needed to reduce bias and improve the quality of evidence, in order to better inform clinical practice and enhance the care and well-being of patients with BCRL.
PURPOSE: A stabilized pemetrexed agent is provided to prevent discoloration or sediment generation by containing acetylcysteine as an antioxidant and sodium citrate as a buffer agent. CONSTITUTION: A stabilized pemetrexed agent comprises pemetrexed or pharmaceutically allowable salt thereof as an active ingredient, N-acetyl-L-cysteine ,and sodium citrate. The concentration ratio of pemetrexed or pharmaceutically allowable salt thereof, N-acetyl-L-cysteine, and sodium citrate is 1-30:0.15-2.0:1.0-15.0. The agent is stored in a solution state. The agent is a liquid formulation for injection contained in a sealed ready-to-use container. [Reference numerals] (AA) Injection water(WFI); (BB) Example 11; (CC) Comparative example 12; (DD) Comparative example 14; (EE) Comparative example 1
U. S. SERIAL NO. 854,306 Filed Nov. 23, 1977 Dkt. No.                 REMOVAL OF BACTERIA                                Abstract This invention relates to an ion exchange column for the removal of bacteria from a liquid medium wherein the column has, as an indicator to indicate when the column capacity for removal of bacteria is exhausted, a filter having submicron pores which will become plugged after a short period of usage with an exhausted bacteria-removing ion exchange column so that pressure build up will noticeably reduce the flow of liquid exiting from the filter thereby indicating to the user that the ion exchange column is exhausted. This invention also relates to a process for removing bacteria from a liquid medium wherein a bacteria containing medium is passed through an ion exchange column capable of removing such bacteria and then through a filter having submicron pores. When the capacity of the ion exchange column for removing bacteria is substantially exhausted, bacteria are removed by the submicron filter which quickly plugs. The build up in pressure, as a result of the plugging of the submicron filter, results in a reduction in the flow of liquid exiting from the filter and thereby indicates to the user that the ion exchange column has become exhausted for its intended purposes.
Couples will have the option to receive the intervention after they complete the follow-up survey. This version of the intervention will not include the booster session, so will last approximately 1 month in total. If they choose to receive the intervention, they will be provided with a tablet computer if they do not have one.
Before enrolling the pregnant women in the intervention group, the informed consent form, the personal information form, the climate change awareness scale for pregnant women and the climate change hope scale (pre-test) will be completed. The researcher will then give a 30-minute training presentation on the climate crisis to the pregnant women individually in the conference room on the third floor of the maternity hospital. Two weeks after the training, the worker will open a meeting session via Microsoft Teams or Google Meet, and a short animated film will be watched on this platform as a reminder. Four weeks after the viewing of the short animation film, another meeting session will be set up via Microsoft Teams or Google Meet and the link to the survey form will be shared online and the final evaluations (post-test - questions on climate change, climate change awareness scale and hope scale for preventing climate change) will be carried out.
The standard practice of the clinic was made. Accordingly, the researcher performed the vein assessment after the participants filled out the questionnaire, and then inserted the 20-G catheter into the inner surface of their forearm without any application. Afterwards, she assessed the pain and anxiety levels of the patients twice before and after the catheter insertion procedure.
Patients receive anti-PD1 or anti-PD-L1 monoclonal antibody therapy either every 3 or 6 weeks, or every 2 or 4 weeks per physicians choice. Patients also receive siltuximab IV over 1 hour on day 1 of each cycle prior to the administration of anti-PD1 or anti-PD-L1 therapy. Treatment repeats either every 3 weeks for up to 8 doses or every 4 weeks for up to 6 doses in the absence of disease progression or unacceptable toxicity. Patients may undergo biopsy and bone scan on study, as well as blood sample collection and CT or MRI throughout the study.
Doxorubicin (DOX) is an effective anticancer agent, yet its clinical utility is hampered by dose-dependent cardiotoxicity. This study explores the cardioprotective potential of Marein (Mar) against DOX-induced cardiac injury and elucidates underlying molecular mechanisms. Neonatal rat cardiomyocytes (NRCMs) and murine models were employed to assess the impact of Mar on DOX-induced cardiotoxicity (DIC). In vitro, cell viability, oxidative stress were evaluated. In vivo, a chronic injection method was employed to induce a DIC mouse model, followed by eight weeks of Mar treatment. Cardiac function, histopathology, and markers of cardiotoxicity were assessed. In vitro, Mar treatment demonstrated significant cardioprotective effects in vivo, as evidenced by improved cardiac function and reduced indicators of cardiac damage. Mechanistically, Mar reduced inflammation, oxidative stress, and apoptosis in cardiomyocytes, potentially via activation of the Focal Adhesion Kinase (FAK)/AKT pathway. Mar also exhibited an anti-ferroptosis effect. Interestingly, Mar did not compromise DOX's efficacy in cancer cells, suggesting a dual benefit in onco-cardiology. Molecular docking studies suggested a potential interaction between Mar and FAK. This study demonstrates Mar's potential as a mitigator of DOX-induced cardiotoxicity, offering a translational perspective on its clinical application. By activating the FAK/AKT pathway, Mar exerts protective effects against DOX-induced cardiomyocyte damage, highlighting its promise in onco-cardiology. Further research is warranted to validate these findings and advance Mar as a potential adjunctive therapy in cancer treatment.
Placebo will be administered as one or two capsules as a single daily dose, based on the patient's weight. Treatment will be for 96 weeks.
After being informed about the study including the potential pros and cons, patients will be given a minimum of 7 days to think about whether they would like to participate in the study. If they would like to participate, and informed consent form will need to be signed, after which the patients will undergo a screening to ensure they meet the inclusion criteria. A 2 week run-in period will take place to let patients get used to filling in an electronic daily diary. Prior to this period, patients will be asked to fill out several questionnaires. After this period, randomisation into either (1) the anal insert group or (2) the care as usual group. Group 1 will then have an 'accommodation' week in which they can try out two different sizes of the anal insert to see which size they would prefer for the treatment period. The treatment period will consist of 8 weeks In which the (1) anal insert group is expected to use the anal inserts and the (2) care as usual group is asked to continue with their treatment as usual. During the treatment period, patients will fill out an electronic daily diary as well as weekly questionnaires.At the end of the 8 week treatment period, patients will fill out additional questionnaires. The follow-up consists of 4 weeks, after which patients will be asked again to fill out several questionnaires.
Each procedure is completed under general anesthesia in lithotomy position. A semi-rigid ureteroscopy is used to place a 0.032-inch guidewire. A pressure measuring ureteral access sheath (UAS) (11-14Fr) is inserted into the proximal ureter along the guidewire without fluoroscopic guidance. The irrigation and suctioning platform will be not used. A 7.5 Fr flexible ureteroscopy is used to break the stone with a holmium laser (fiber diameter 200 µm). A basket is used to remove the stone fragments. A 4-6Fr ureteral stent is left for 2 weeks after the operation. Stone composition is analyzed. If the UAS is failed to be placed, ureteral stent will be placed for 2 weeks and a second stage traditional f-URL will be performed.
Intensity Modulated Radiation Therapy (IMRT) Delivery of whole-pleura radiation doses beginning with 1) 45 Gy to low-risk region and 60-66 Gy to high-risk region; then 2) the same dosing regimen as above with a third dosing level, 50 Gy to an intermediate-dosing region. Every weekday (Monday-Friday) for up to 5 weeks, lasting about 45-60 minutes.
The most common chronic liver illness, non-alcoholic fatty liver disease (NAFLD), refers to a range of abnormalities of the liver with varying degrees of steatosis. When the clinical symptoms including liver damage, inflammation, and fibrosis, are added to the initial steatosis, NAFLD becomes non-alcoholic steatohepatitis (NASH), the problematic and severe stage. The diagnosis of NASH at the right time could therefore effectively prevent deterioration of the disease. Considering that platelets (PLTs) could migrate to the sites of inflamed liver sinusoids with oxidative stress during the development of NASH, we purified the PLTs from fresh blood and engineered their surface with hydrogen peroxide (H2O2) responsive fluorescent probe (5-DP) through lipid fusion. The engineered PLT-DPs were recruited and trapped in the inflammation foci of the liver with NASH through interaction with the extracellular matrix, including hyaluronan and Kupffer cells. Additionally, the fluorescence of 5-DP on the surface of PLT-DP was significantly enhanced upon reacting with the elevated level of H2O2 in the NASH liver. Thus, PLT-DP has great promise for NASH fluorescence imaging with high selectivity and sensitivity.
Serotonin-norepinephrine reuptake inhibitors (SNRIs), including FETZIMA, can precipitate serotonin syndrome, a potentially life-threatening condition. The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. John’s Wort) and with drugs that impair metabolism of serotonin, i.e., MAOIs [see Contraindications (4), Drug Interactions (7.1)]. Serotonin syndrome can also occur when these drugs are used alone. 

Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). 

The concomitant use of FETZIMA with MAOIs is contraindicated. In addition, do not initiate FETZIMA in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue. No reports involved the administration of methylene blue by other routes (such as oral tablets or local tissue injection). If it is necessary to initiate treatment with a MAOI such as linezolid or intravenous methylene blue in a patient taking FETZIMA, discontinue FETZIMA before initiating treatment with the MAOI [see Dosage and Administration (2.5, 2.6) and Contraindications (4), Drug Interactions (7.1)].

Monitor all patients taking FETZIMA for the emergence of serotonin syndrome. Discontinue treatment with FETZIMA and any concomitant serotonergic agents immediately if the above events occur and initiate supportive symptomatic treatment. If concomitant use of FETZIMA with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms.
The invention discloses a co-crystal of acetazolamide and proline and a preparation method thereof, and relates to the field of pharmaceutical co-crystals. The molecular formula of the pharmaceutical co-crystal is [ C ] 4 H 6 N 4 O 3 S 2 ·C 5 H 9 NO 2 ]The basic structural unit is composed of one acetazolamide molecule and one proline molecule. The pharmaceutical co-crystal belongs to a triclinic system and has a space group of P‑ 1. The pharmaceutical co-crystal is prepared by taking acetazolamide and proline as raw materials and respectively adopting a cooling method and a solvent volatilization method. The pharmaceutical co-crystal improves the solubility of acetazolamide and is beneficial to improving the bioavailability of acetazolamide. Because no solvent molecules exist in the eutectic structure, the eutectic structure can still keep stable after being placed for a long time under the condition of room temperature. The preparation method and the process route of the pharmaceutical co-crystal are simple and feasible, and are convenient for large-scale production.
Subjects began Remodulin at 2 ng/kg/min subcutaneously (SC) or intravenously (IV) and were optimized to their maximum tolerated dose (MTD) of Remodulin. Subjects were then transitioned to Orenitram XR tablets (oral) based upon their Remodulin dose. Subjects were optimized on Orenitram therapy to a MTD. There were no maximum Remodulin or Orenitram doses specified during the study.
Arrangements are provided for “smart” functionality with “dumb” containers, such as for tracking medication use to determine adherence. An acoustic emitter such as a whistle is engaged with a container such as an eye drop bottle. An event such as dispensing medication or opening the container causes a characteristic acoustic emission, such as an ultrasonic pitch of specific frequency. The emitter may be purposefully configured to produce the emission, may operate so that the emission is a natural consequence of dispensing medication (or other event), and may operate transparently to the user. The emitter may be part of a larger remote, such as a squeezable air-filled shell with an aperture to accept the container. A cell phone or other station receives the acoustic emission, and if a processor thereof determines that the emission is characteristic of the emitter the event is recorded, transmitted, displayed, or otherwise registered.
A drug delivery device with dose delivery sensing capability is provided. The sensed element is attached to a dose setting member of the device. The sensed elements include surface features radially spaced from one another. The rotation sensor is attached to an actuator of the device. The rotation sensor includes a movable element contactable against the surface feature. The rotation sensor is configured to generate a signal in response to movement of the movable element across the surface feature during rotation thereof. A controller is operatively coupled to the rotation sensor and, in response to receiving the generated signal, the controller is configured to determine a number of surface features of the movable element that pass the rotation sensor during dose delivery. This number can be correlated to the amount of dose delivered. The sensing can be provided in a module or integrated in the device.
BACKGROUND: Low-level transcutaneous stimulation of the auricular branch of the vagus nerve at the tragus is antiarrhythmic and anti-inflammatory in animals and humans. Preliminary studies show that transcutaneous vagus nerve stimulation (tVNS) is beneficial in animal models of postural tachycardia syndrome (POTS).
OBJECTIVES: In this study the authors conducted a sham-controlled, double-blind, randomized clinical trial to examine the effect of tVNS on POTS over a 2-month period relative to sham stimulation.
METHODS: tVNS (20 Hz, 1 mA below discomfort threshold) was delivered using an ear clip attached to either the tragus (active; n = 12) or the ear lobe (sham; n = 14) for 1 hour daily over a 2-month period. Postural tachycardia was assessed during the baseline and 2-month visit. Heart rate variability based on 5-minute electrocardiogram, serum cytokines, and antiautonomic autoantibodies were measured at the respective time points.
RESULTS: Mean age was 34 ± 11 years (100% female; 81% Caucasian). Adherence to daily stimulation was 83% in the active arm and 86% in the sham arm (P > 0.05). Postural tachycardia was significantly less in the active arm compared with the sham arm at 2 months (mean postural increase in heart rate 17.6 ± 9.9 beats/min vs 31.7 ± 14.4 beats/min; P = 0.01). Antiadrenergic autoantibodies and inflammatory cytokines were lower in the active arm compared with the sham arm at 2 months (P < 0.05). Heart rate variability was better in the active arm. No device-related side effects were observed.
CONCLUSIONS: Our results support the emerging paradigm of noninvasive neuromodulation to treat POTS. Mechanistically, this effect appears to be related to reduction of antiautonomic autoantibodies and inflammatory cytokines, and improvement in autonomic tone. Further studies are warranted. (Autoimmune Basis for Postural Tachycardia Syndrome; NCT05043051).